{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:40:47Z","timestamp":1774273247301,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007434","name":"Suzuken Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004016","name":"Japan Prize Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004298","name":"Secom Science and Technology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005928","name":"Daiwa Securities Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012630","name":"Life Science Foundation of Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012630","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Theoretical Biology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jtbi.2022.111403","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T02:03:08Z","timestamp":1672192988000},"page":"111403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Relationship between the inclusion\/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors"],"prefix":"10.1016","volume":"561","author":[{"given":"Daiki","family":"Tatematsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa","family":"Akao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeongki","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Iwami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Ejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoya","family":"Iwanami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtbi.2022.111403_b0005","first-page":"85","article-title":"Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials","volume":"3","author":"Akao","year":"2021","journal-title":"Transl. Regul. Sci."},{"key":"10.1016\/j.jtbi.2022.111403_b0010","doi-asserted-by":"crossref","unstructured":"Baral, S., R. Antia, and N.M. Dixit, A dynamical motif comprising the interactions between antigens and CD8 T cells may underlie the outcomes of viral infections. Proceedings of the National Academy of Sciences, 2019. 116(35): p. 17393-17398.","DOI":"10.1073\/pnas.1902178116"},{"issue":"9","key":"10.1016\/j.jtbi.2022.111403_b0015","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/imcb.12161","article-title":"Modeling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct-acting antiviral agents","volume":"96","author":"Baral","year":"2018","journal-title":"Immunol. Cell Biol."},{"issue":"8","key":"10.1016\/j.jtbi.2022.111403_b0020","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S1473-3099(20)30287-5","article-title":"Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study","volume":"20","author":"Bi","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"6","key":"10.1016\/j.jtbi.2022.111403_b0025","doi-asserted-by":"crossref","first-page":"e1010630","DOI":"10.1371\/journal.ppat.1010630","article-title":"Modeling recapitulates the heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the innate immune and CD8 T-cell responses between patients experiencing mild and severe symptoms","volume":"18","author":"Chatterjee","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jtbi.2022.111403_b0030","doi-asserted-by":"crossref","unstructured":"Conway, J.M. and A.S. Perelson, Post-treatment control of HIV infection. Proceedings of the National Academy of Sciences, 2015. 112(17): p. 5467-5472.","DOI":"10.1073\/pnas.1419162112"},{"issue":"8","key":"10.1016\/j.jtbi.2022.111403_b0035","doi-asserted-by":"crossref","first-page":"e1008064","DOI":"10.1371\/journal.pcbi.1008064","article-title":"Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection","volume":"16","author":"Desikan","year":"2020","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.jtbi.2022.111403_b0040","series-title":"Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load","author":"Gon\u00e7alves","year":"2020"},{"issue":"47","key":"10.1016\/j.jtbi.2022.111403_b0045","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc7112","article-title":"Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response","volume":"6","author":"Goyal","year":"2020","journal-title":"Sci. Adv."},{"issue":"21","key":"10.1016\/j.jtbi.2022.111403_b0050","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early Treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.jtbi.2022.111403_b0055","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6506","key":"10.1016\/j.jtbi.2022.111403_b0060","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jtbi.2022.111403_b0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jtbi.2022.111403_b0070","series-title":"Activation of Viruses by Host Proteases","first-page":"71","article-title":"Priming time: how cellular proteases arm coronavirus spike proteins","author":"Hoffmann","year":"2018"},{"issue":"7","key":"10.1016\/j.jtbi.2022.111403_b0075","doi-asserted-by":"crossref","first-page":"e1003660","DOI":"10.1371\/journal.pmed.1003660","article-title":"Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: a modeling study","volume":"18","author":"Iwanami","year":"2021","journal-title":"PLoS Med."},{"issue":"6","key":"10.1016\/j.jtbi.2022.111403_b0080","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jtbi.2022.111403_b0085","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41591-022-01780-9","article-title":"Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults","volume":"28","author":"Killingley","year":"2022","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.jtbi.2022.111403_b0090","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e142","article-title":"Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the First 28 patients from the korean cohort study on COVID-19","volume":"35","author":"Kim","year":"2020","journal-title":"J. Korean Med. Sci."},{"issue":"3","key":"10.1016\/j.jtbi.2022.111403_b0095","doi-asserted-by":"crossref","first-page":"e3001128","DOI":"10.1371\/journal.pbio.3001128","article-title":"A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2","volume":"19","author":"Kim","year":"2021","journal-title":"PLoS Biol."},{"issue":"10","key":"10.1016\/j.jtbi.2022.111403_b0100","doi-asserted-by":"crossref","first-page":"e202101049","DOI":"10.26508\/lsa.202101049","article-title":"Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection","volume":"4","author":"Kim","year":"2021","journal-title":"Life Sci. Alliance"},{"issue":"7","key":"10.1016\/j.jtbi.2022.111403_b0105","doi-asserted-by":"crossref","first-page":"e3001333","DOI":"10.1371\/journal.pbio.3001333","article-title":"Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies","volume":"19","author":"Kissler","year":"2021","journal-title":"PLoS Biol."},{"issue":"7824","key":"10.1016\/j.jtbi.2022.111403_b0110","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-020-2324-7","article-title":"Respiratory disease in rhesus macaques inoculated with SARS-CoV-2","volume":"585","author":"Munster","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jtbi.2022.111403_b0115","doi-asserted-by":"crossref","unstructured":"N\u00e9ant, N., et al., Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proceedings of the National Academy of Sciences, 2021. 118(8): p. e2017962118.","DOI":"10.1073\/pnas.2017962118"},{"issue":"5","key":"10.1016\/j.jtbi.2022.111403_b0120","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2021.24939","article-title":"Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial","volume":"327","author":"O'Brien","year":"2022","journal-title":"J. Am. Med. Assoc."},{"issue":"12","key":"10.1016\/j.jtbi.2022.111403_b0125","doi-asserted-by":"crossref","first-page":"e1008461","DOI":"10.1371\/journal.pcbi.1008461","article-title":"Targeting TMPRSS2 and Cathepsin B\/L together may be synergistic against SARS-CoV-2 infection","volume":"16","author":"Padmanabhan","year":"2020","journal-title":"PLoS Comput. Biol."},{"issue":"2","key":"10.1016\/j.jtbi.2022.111403_b0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s43588-022-00198-0","article-title":"Modeling how antibody responses may determine the efficacy of COVID-19 vaccines","volume":"2","author":"Padmanabhan","year":"2022","journal-title":"Nat. Comput. Sci."},{"issue":"1","key":"10.1016\/j.jtbi.2022.111403_b0135","doi-asserted-by":"crossref","first-page":"14210","DOI":"10.1038\/s41598-022-18244-2","article-title":"A simple model of COVID-19 explains disease severity and the effect of treatments","volume":"12","author":"Sanche","year":"2022","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.jtbi.2022.111403_b0140","doi-asserted-by":"crossref","first-page":"e0019222","DOI":"10.1128\/aac.00192-22","article-title":"Characterizing SARS-CoV-2 viral clearance kinetics to improve the design of antiviral pharmacometric studies","volume":"66","author":"Watson","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jtbi.2022.111403_b0145","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7824","key":"10.1016\/j.jtbi.2022.111403_b0150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"7809","key":"10.1016\/j.jtbi.2022.111403_b0155","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jtbi.2022.111403_b0160","unstructured":"Yotsuyanagi, H., et al., Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: A protocol for a multicenter, randomized, double-blind, placebo-controlled, phase 3 study (the SCORPIO-SR trial). medRxiv, 2022: p. 2022.07.15.22277670."},{"issue":"15","key":"10.1016\/j.jtbi.2022.111403_b0165","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2020.3204","article-title":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore","volume":"323","author":"Young","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"12","key":"10.1016\/j.jtbi.2022.111403_b0170","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMc2001737","article-title":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients","volume":"382","author":"Zou","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Theoretical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519322003940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519322003940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:36:28Z","timestamp":1758386188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022519322003940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":34,"alternative-id":["S0022519322003940"],"URL":"https:\/\/doi.org\/10.1016\/j.jtbi.2022.111403","relation":{},"ISSN":["0022-5193"],"issn-type":[{"value":"0022-5193","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between the inclusion\/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Theoretical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtbi.2022.111403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111403"}}